Future Perspectives of Pulmonary Hypertension Treatment

Chih Hsin Hsu, Wei Chun Huang, Wei Ting Chang

研究成果: Review article同行評審

6 引文 斯高帕斯(Scopus)

摘要

Since the discovery of three major pathophysiological mechanisms of pulmonary arterial hypertension (PAH), including prostacyclin, endothelin and nitric oxide pathways, the therapeutic options for PAH have increased. Nevertheless, despite these advances, the prognosis remains unsatisfactory for many patients with PAH. With the progress of both pre-clinical and clinical research on PAH, several novel therapeutic targets have been identified for the treatment of PAH. In this study, we review updated information of novel pathophysiological pathways of pulmonary hypertension, mainly focusing on WHO Group I PAH. Drugs based on these pathways are currently under clinical or pre-clinical investigation, however they have been approved for clinical use. Large clinical trials are required to validate the clinical safety and effects of these novel therapies.

原文English
頁(從 - 到)435-442
頁數8
期刊Acta Cardiologica Sinica
38
發行號4
DOIs
出版狀態Published - 2022 7月

All Science Journal Classification (ASJC) codes

  • 心臟病學與心血管醫學

指紋

深入研究「Future Perspectives of Pulmonary Hypertension Treatment」主題。共同形成了獨特的指紋。

引用此